UPyTher

Blisters on my feet from walking from one interesting meeting to the next. We joined this 4TU.Startups mission to set foot to US ground and pave the way for new partnerships....And yet we succeeded!

Farewell, Boston. Hello, Toronto! The first leg of our journey with 4TU.Startups across the US and Canada has concluded. We spent four inspiring days filled with meaningful interactions and new connections in the Boston area. Special thanks to Nelya Melnitchouk, MD from Brigham and Women's Hospital for taking the time to meet with us and discuss UPyTher's innovative solutions to improve treatment outcomes for patients with peritoneal cancer. Now on to the next chapter... Toronto, here we come! Geert van Almen | Peter-Paul Fransen | The Gate | Sebastiaan Huntjens | Valeria Saar-Kovrov, PhD | 4TU.Federation

Excited to attend the 14th international congress PSOGI/ISSPP in Lyon and meet with all globally renowned experts in the field of peritoneal surface oncology. We will showcase our gel-based technology that is tailored to optimize the delivery and retention of therapeutics inside the peritoneal cavity, with the aim to overcome the complexities of intraperitoneal therapy and improve therapeutic outcomes. Visit us at our poster (PO19) on Thursday Sept 26th, or let's have a chat during the conference. We look forward meeting you in Lyon! 14th international congress PSOGI/ISSPP | Peritoneal Surface Oncology Group International (PSOGI) | Peter-Paul Fransen | Frans Lichtenauer

UPyTher was fortunate to celebrate many successes in H1-2024. A major shout out to the Smart BioMaterials Consortium (SBMC) for highlighting all these achievements in this short interview. It was fun to do and to celebrate this with all members of the SBMC. We are already looking ahead to celebrate our next success together. Stay tuned and follow UPyTher here or visit the website www.upyther.com.

UPyTher was fortunate to celebrate many successes in H1-2024. A major shout out to the Smart BioMaterials Consortium (SBMC) for highlighting all these achievements in this short interview. It was fun to do and to celebrate this with all members of the SBMC. We are already looking ahead to celebrate our next success together. Stay tuned and follow UPyTher here or visit the website www.upyther.com.

📢 Exciting News!! UPyTher received the prestigious Gerard & Anton Award as 'One to Watch' startup company in the Brainport Region. The award committee described our work as truly life-changing for patients with peritoneal cancer. We feel honored to be rated among the 10 most promising companies in the Brainport Region. Innovation Origins NL | Gerard & Anton | The Gate | Stimulus Programmamanagement | Metropoolregio Eindhoven | Patricia Y.W. Dankers | Peter-Paul Fransen | Frans Lichtenauer

UPyTher warmly welcomes Helmuth van Es on its Board of Advisors. Helmuth brings over 30 years of experience in the biotech industry. His addition to the team will boost the growth of UPyTher and advancement of the company's lead product UPT-211 to the clinical stage.

UPyTher announces seed financing to advance the treatment of peritoneal cancer. For more information read the full article or visit our brand new website: www.upyther.com

Proud to be a member of the SBMC community. A major shoutout to SBMC for supporting UPyTher on its journey to make peritoneal cancer a treatable disease.

Funding from Europe and the Province of North Brabant for Eindhoven based UPyTher and SupraPolix BV to bring novel and improved therapy to patients with peritoneal cancer, with a total budget of EUR 2.8 million. SupraPolix develops tailored injectable hydrogel gel solutions for various medical applications. Building on this hydrogel technology UPyTher is pioneering an innovative treatment for patients with peritoneal cancer that enables a very efficient delivery of medicines into the peritoneal cavity.    Within the project INJECTOGELS SupraPolix and UPyTher work together to scale-up the production processes of these injectable gels and confirm their safe use as drug delivery platform for intraperitoneal therapy. At the end of the project, UPyTher’s first product for intraperitoneal therapy can be manufactured according to regulatory standards and is supported with a robust nonclinical data package that allows clinical evaluation for patients with peritoneal metastases from colorectal origin. Stimulus Programmamanagement | UPyTher | SupraPolix BV